Betting on hepatitis C: how financial speculation in drug development influences access to medicines

Betting on hepatitis C: how financial speculation in drug development influences access to medicines

Victor Roy and Lawrence King argue that the acquisition strategies of drug companies magnify development costs and leave the public paying twice—for research and high priced medicines

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:BMJ (Online) 2016-07, Vol.354, p.i3718-i3718
Hauptverfasser: Roy, Victor, King, Lawrence
Format: Artikel
Sprache:eng
Schlagworte:
Antiviral Agents - economics
Budgets
Corporate profits
Costs
Drug Discovery - economics
Drug Industry - economics
Drugs
Earnings
FDA approval
Hepatitis C
Hepatitis C - drug therapy
Humans
Pharmaceutical industry
Prices
Profit margins
R&D
Research & development
Research & development expenditures
Sofosbuvir - economics
Stockholders
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Victor Roy and Lawrence King argue that the acquisition strategies of drug companies magnify development costs and leave the public paying twice—for research and high priced medicines
ISSN:1756-1833
1756-1833
DOI:10.1136/bmj.i3718